Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-10
2008-11-25
Desai, Rita J (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S082000
Reexamination Certificate
active
07456194
ABSTRACT:
The present invention provides for pyrazolopurine-based tricyclic compounds having the formula (I),wherein R1, R2, R3, and R6are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.
REFERENCES:
patent: 6933294 (2005-08-01), Belema et al.
patent: 2003/0045545 (2003-03-01), Gerster et al.
patent: 2003/0078277 (2003-04-01), Hibi et al.
patent: 2003/0212093 (2003-11-01), Gerster et al.
patent: 2004/0204432 (2004-10-01), Qiu et al.
patent: 2005/0038054 (2005-02-01), Combs et al.
patent: 2005/0101626 (2005-05-01), Pitts et al.
patent: WO 01/00587 (2001-01-01), None
patent: WO2004/106293 (2004-12-01), None
U.S. Appl. No. 11/271,598, filed Nov. 10, 2005, Das et al., Not yet published.
J. Burke et al., “BMS-34541 is a Highly Selective Inhibitor of IKB Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-KB-Dependent Transcription in Mice”, Journal of Biological Chemistry, vol. 278, No. 3, pp. 1450-1456, 2003.
J. Burke, “Targeting IKB Kinase for the Treatment of Inflammatory and Other Disorders”, Current Opinion in Drug Discovery & Development, vol. 6, No. 5, pp. 720-728, 2003.
I. Nahar et al., “Infliximab Treatment of Rheumatoid Arthritis and Crohn's Disease”, Annals of Pharmacotherapy, vol. 37, pp. 1256-1265, 2003.
J. Braun et al., “Overview of the Use of the Anti-TNF Agent Infliximab in Chronic Inflammatory Diseases”, Expert Opinion Biol. Ther., vol. 3, No. 1, pp. 141-168, 2003.
G. Keating et al., “Infliximab an Updated Review of its Use in Crohn's Disease and Rheumatoid Arthritis”, Biodrugs, vol. 16, No. 2, pp. 111-148, 2002.
W. Sandborn et al., “Infliximab in the Treatment of Crohn's Disease: A User's Guide for Clinicians”, American Journal of Gastroenterology, vol. 97, No. 12, pp. 2962-2972, 2002.
J. Weinberg, “An Overview of Infliximab, Etanercept, Efalizumab, and Alefacept as Biologic Therapy for Psoriasis”, Clinical Therapeutics, vol. 25, No.10, pp. 2487-2505, 2003.
Belema Makonen
Dyckman Alaric
Gill Patrice
Kempson James
Pitts William J.
Bristol--Myers Squibb Company
Desai Rita J
Van Atten Mary
LandOfFree
Imidazo-fused oxazolo [4,5- b ]pyridine and imidazo-fused... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazo-fused oxazolo [4,5- b ]pyridine and imidazo-fused..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazo-fused oxazolo [4,5- b ]pyridine and imidazo-fused... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4038150